Carefusion Corp: (NYSE: CFN)

$34.40

0.23 (0.66%)

Volume 529,940

May 23 10:24 AM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		33.70 - 34.43
	
		52wk Low - High
		23.77 - 35.61
	
		Previous Close
		34.17
	
		Avg. Volume
		2,180,901
	
		Industry
		MED PRODUCTS
	
		Market Cap
		7.61 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.48
	
		PE (Forward)
		16.04
	
		Current Year Est.
		2.13
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		184 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/21/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            16.04
                        
                            PEG Ratio
                            1.63
                        
                            Current Year Est.
                            2.13
                        
                            Current Quarter Estimate
                            0.56
                        
                            Most Accurate Estimate
                            0.56
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            1.77
                        
                            Expected Earnings Growth
                            9.86%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
CareFusion is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris ? IV pumps, Pyxis ? automated dispensing and patient identification systems, AVEA ? and Pulmonetic Systems ventilation and respiratory products, ChloraPrep ? and MedMined services for infection prevention, neurological monitoring and diagnostic products, V. Mueller ? surgical instruments, and an extensive line of products that support interventional medicine. The company is headquartered in San Diego, California.   
Full CFN Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
CFN Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Average Estimate	0.56	0.48	2.13	2.36
Number of Estimates	13	7	14	13
Low Estimate	0.54	0.45	2.11	2.30
High Estimate	0.59	0.50	2.16	NA
Year Ago EPS	0.51	NA	1.78	2.13
EPS Growth	10.41%	NA	19.70%	10.98%

More CFN Estimates

Average Earnings Estimates for CFN

EPS Growth for CFN

Industry Analysis

Name	Symbol	Previous Close
CAREFUSION CORP	CFN	34.17
ATRICURE INC	ATRC	9.14
CONCEPTUS INC	CPTS	30.94
INVIVO THERAPT	NVIV	2.90
TRANS1 INC	TSON	1.80
ABAXIS INC	ABAX	43.51
ADVAXIS INC	ADXS	0.04
BAXTER INTL	BAX	72.30
BIO-RAD LABS -A	BIO	115.39
BIOLIFE SOL INC	BLFS	0.37

Sector:Medical>> Industry:MED PRODUCTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Stryker in a Rough Patch

Apr 12, 2013

SNN Acquires Brazilian Distributor

Apr 04, 2013

Smith & Nephew Extends Portfolio

Mar 27, 2013

Covidien to Repurchase Shares

Mar 27, 2013

SNN Rolls Out Journey II BCS Knee

Mar 26, 2013

St. Jude Prices Senior Notes

Mar 25, 2013

Pediatric Exclusivity for Hospira's Drug

Mar 19, 2013

Covidien Expands Hernia Care Line

Mar 15, 2013

More CFN Zacks Commentary

Financials

EPS TTM	1.77
Sales	3,601
Net Income	362
Price/Earnings	19.31
Price/Book	1.38
Price/Cash Flow	12.64
Price/Sales	2.15

More CFN Financials

News

CareFusion (CFN) Could Break Through $35.45 Resistance Level - Freshbrewedmedia

May 23, 2013

CareFusion Foundation Announces Clinical Excellence Grant Recipients - Pr Newswire

May 22, 2013

Shares of CareFusion Are Moving Higher on 1.3x Above-Average Volume (CFN) - Financial News Network Online - Unusual Volume

May 22, 2013

Stock Investors Bid Up Shares of CareFusion, Up 1.6% - Financial News Network Online - Market Movers

May 22, 2013

Analysis of Relative Performance in the Health Care Equipment Industry for Shares of Thoratec (THOR, HTWR, EW, ABMD, CFN) - Financial News Network Online - News Corner

May 21, 2013

CareFusion Earnings Review: 11 Days after Announcement Shares Down 0.8% (CFN) - Comtex Smartrend(R)

May 20, 2013

CareFusion Earnings In Retrospect: Down 0.8% in the Last 9 Days (CFN) - Financial News Network Online - Earnings Lookback

May 18, 2013

CareFusion (CFN) Showing Bearish Technicals But Could Fall Through $33.08 Support - Freshbrewedmedia

May 17, 2013

See All News Stories on CFN

Broker Recommendations

Current ABR	1.93
ABR (Last Week)	1.93
# of recs in ABR	14
Average Target Price	36.00
Industry Rank by ABR	184 out of 265
Rank in Industry	63 out of 73

More CFN Broker Recommendations

Day Low - High	33.70 - 34.43
52wk Low - High	23.77 - 35.61
Previous Close	34.17
Avg. Volume	2,180,901
Industry	MED PRODUCTS
Market Cap	7.61 B
Div - Yield	0.00 - 0.00
Beta	0.48
PE (Forward)	16.04
Current Year Est.	2.13
Quarterly Earnings ESP	0.00%

PE (Forward)	16.04
PEG Ratio	1.63
Current Year Est.	2.13
Current Quarter Estimate	0.56
Most Accurate Estimate	0.56
Earnings ESP	0.00%
Next Earnings Report Date	08-08-2013
EPS Last Year	1.77
Expected Earnings Growth	9.86%

Username: Password:

Remember me [?]

Carefusion Corp: (NYSE: CFN)

$34.40

0.23 (0.66%)

Volume 529,940

May 23 10:24 AM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED PRODUCTS

Zacks Commentary

Financials

News

Broker Recommendations